Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eyenovia, Inc. Provides Corporate Update on Pipeline with Recent and Upcoming Milestones

06/15/2021 | 08:22am EDT

Eyenovia, Inc. provided a corporate update on its pipeline with recent and upcoming milestones. Eyenovia previously announced initial topline data from its Phase 3 VISION-1 clinical trial, which evaluated the company's proprietary pilocarpine solution, administered via the Optejet, for the treatment of presbyopia. The company is providing additional details from the study. The VISION-1 study evaluated the safety and efficacy of Eyenovia's MicroLine presbyopia microdose formulations versus placebo, all administered via the company's proprietary Optejet delivery Micro-Array Print technology. The VISION-1 study evaluated the safety and efficacy of Eyenovia's 1% and 2% pilocarpine Micro-Array Print (MAP) formulations versus placebo, all administered via the company's proprietary Optejet dispenser. VISION-1 is the third Phase 3 study demonstrating the utility of the company's MAP technology in improving the therapeutic index of topical ophthalmic drugs. To support the submission of a New Drug Application (NDA), the company is on track to initiate a second Phase 3 registrational trial, VISION-2, later this year. VISION-2 will be a double-masked, placebo-controlled, cross-over superiority trial designed to enroll 120 patients randomized between 2% pilocarpine and placebo cohorts. Topline data is anticipated in mid-2022. It is estimated that as many as 18 million people between the ages of 40-55 suffer from presbyopia in the U.S. alone, suggesting a multi-billion-dollar addressable market for MicroLine, if approved.


© S&P Capital IQ 2021
All news about EYENOVIA, INC.
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
MT
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug Mydcombi™ to Eyenovi..
CI
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
PU
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic..
CI
08/12EYENOVIA : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evalu..
PU
08/11EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Fi..
AQ
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30,..
CI
08/11Eyenovia Reports Second Quarter 2021 Financial Results
GL
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 5,24 M - -
Net income 2021 -23,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,49x
Yield 2021 -
Capitalization 117 M 117 M -
Capi. / Sales 2021 22,3x
Capi. / Sales 2022 12,0x
Nbr of Employees 33
Free-Float 63,8%
Chart EYENOVIA, INC.
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,50 $
Average target price 15,50 $
Spread / Average Target 244%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.-25.74%117
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604